Adhera Therapeutics, Inc. (OTCPK: ATRX) has announced the issuance of a new European patent for MLR-1019 (armesocarb), aimed at treating dyskinesia related to Parkinson's disease. This patent broadens Adhera's portfolio, which now includes 11 issued patents and 8 pending. The company plans to initiate Phase 2a clinical trials in Eastern Europe, leveraging extensive historical data from a related drug, mesocarb. CEO Andrew Kucharchuk emphasized the significance of this patent in their development strategy as they explore solutions for Parkinson’s-related symptoms.
Adhera Therapeutics (OTCPK: ATRX) updates its shareholders on the clinical development of MLR-1019 for Parkinson’s disease and MLR-1023 for Type 1 diabetes. MLR-1019 is the only drug candidate targeting both movement and non-movement symptoms of PD. Its Phase 2a trial is set to begin in Eastern Europe. MLR-1023, previously for Type 2 diabetes, will transition to Type 1 diabetes due to its unique benefits for pancreatic beta cells and a longer market exclusivity. Recently, Dr. Andrew G. Reaume joined the Board, enhancing the company's capabilities, while plans to move to OTCQB and eventually NASDAQ are underway.
Adhera Therapeutics, Inc. (OTCPK: ATRX) announced the appointment of Andrew G. Reaume, Ph.D., MBA, to its Board of Directors. Reaume, co-founder and CEO of Melior Discovery, brings over 25 years of pharmaceutical experience, including raising $15 million in capital and closing $40 million in partnerships. Adhera is advancing its clinical trials for MLR-1019 (Parkinson's disease) and MLR-1023 (Type 1 diabetes). The company's focus is on drug candidates qualifying for accelerated development pathways, with significant investments already made in these therapeutic areas.
Adhera Therapeutics (OTCPK: ATRX) has announced the licensing of MLR-1023 from Melior Pharmaceuticals to develop a treatment for Type 1 diabetes, targeting C-peptide positive patients (320,000-480,000 in the U.S.). MLR-1023, a lyn kinase activator, has shown safety in over 700 patients during previous trials. The company plans to initiate a Phase 2 trial, leveraging existing data and previous research suggesting its potential to induce beta cell proliferation, thus potentially reducing insulin dependency for affected patients.
Adhera Therapeutics (OTCPK: ATRX) has signed a definitive license agreement with Melior Pharmaceuticals II for the development of MLR-1019 (armesocarb), targeting both movement and non-movement symptoms of Parkinson's Disease (PD). MLR-1019, an active enantiomer in mesocarb, is expected to enter a Phase 2a clinical trial, leveraging decades of safety data from its predecessor. The drug aims to enhance L-DOPA therapy and mitigate associated dyskinesia, positioning it uniquely in the market. Adhera gains exclusive rights to the intellectual property, with royalties owed upon commercialization.
Adhera Therapeutics (ATRX) has signed a Letter of Intent to acquire MLR-1019 (armesocarb) from Melior Pharmaceuticals II for the treatment of Parkinson’s Disease (PD). MLR-1019, a Phase 2-ready product, promises to be the first drug to tackle both motor and non-motor symptoms of PD. Previously sold in Europe for 37 years, mesocarb (the API of MLR-1019) has been shown to have a strong safety profile. The acquisition aims to expand Adhera’s portfolio beyond oncology, with expectations to improve the quality of life for PD patients.
Adhera Therapeutics (OTCPK: ATRX) announced the appointment of Trond K. Waerness to its Board of Directors, effective April 23, 2021. Waerness, with over two decades of pharmaceutical experience, has worked with major companies like Glaxo-Wellcome and Novartis. His expertise spans various aspects of pharmaceutical commercialization, including sales and marketing. CEO Andrew Kucharchuk expressed confidence in Waerness's ability to identify and manage new products, which could significantly aid Adhera's growth strategy. The company emphasizes the importance of operational and financial leadership in navigating future opportunities.